Ablynx
Ablynx is a Belgian biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments.
The company currently has approximately 40 proprietary and partnered programs in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease.
Ablynx has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Genzyme, Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceutical.
Latest Ablynx News & Features
12 November 2019
5 February 2019
3 September 2018
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze